Previous 10 | Next 10 |
SAN CARLOS, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced the publication of abstracts reporting clinical data and trial design for tumor i...
Iovance Biotherapeutics ( NASDAQ: IOVA ) on Thursday said it had submitted a rolling biologics license application (BLA) to the U.S. FDA for its cancer therapy lifileucel for the treatment of advanced melanoma, the most serious type of skin cancer. IOVA said it expects to ...
First TIL Therapy BLA Submission Initiated with U.S. Food and Drug Administration Complete BLA Submission on Track for Fourth Quarter 2022 SAN CARLOS, Calif., Aug. 25, 2022 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company...
Shares have lost half of their value since my March 2021 update. Currently, in ROTY we own 8% portfolio weighting with 20% gain. Key pivotal readouts are coming up year end (anti PD-1 failed melanoma) and Q1 2023 (CERPASS CSCC). Recent developments strengthen bullish thesis, inclu...
Iovance Biotherapeutics, Inc. (IOVA) Q2 2022 Earnings Conference Call August 04, 2022 04:30 PM ET Company Participants Sara Pellegrino - Senior Vice President, Investor & Public Relations & Corporate Communications Fred Vogt - Interim President & Chief Ex...
Iovance Biotherapeutics ( NASDAQ: IOVA ) is down 6% in after-hours trading after its Q2 2022 financial results missed on the bottom line . Its net loss in the quarter widened ~22% to $99.3M (-$0.63 per share vs. -$0.53 year-ago period). The company recorde...
Iovance Biotherapeutics press release ( NASDAQ: IOVA ): Q2 GAAP EPS of -$0.63 misses by $0.02 . For further details see: Iovance Biotherapeutics GAAP EPS of -$0.63 misses by $0.02
First Biologics License Application (BLA) Submission on Track in August 2022 SAN CARLOS, Calif., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies (tumor infiltrat...
SAN CARLOS, Calif., July 27, 2022 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, will report its second quarter financial results on Thursday, August 4, 2022. Management will host a c...
Iovance is a leader in TIL cell therapy for solid tumor patients. Iovance is readying its BLA for lifileucel in treatment of melanoma. Iovance has adequate financial footing for its near term needs but little margin for error. This is my first take on Iovance ( IOVA ...
News, Short Squeeze, Breakout and More Instantly...
Iovance Biotherapeutics Inc. Company Name:
IOVA Stock Symbol:
NASDAQ Market:
Iovance Biotherapeutics Inc. Website:
2024-07-26 10:45:04 ET Pacific Biosciences of California Inc (PACB) PACB is trading UP for the last 5 days, and it at trading at $2.10 with volume of 3,952,245 and a one day change of $0.19 (9.97%). Pacific Biosciences of California Inc has a 52-week low of 1.16 and a 52-week high o...
2024-07-14 05:45:00 ET Biotech stocks like Iovance Biotherapeutics (NASDAQ: IOVA) often look appealing because they could experience enormous growth in relatively short periods of time. Plus, over the long term, successful biotech companies have the opportunity to blossom into large...